



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT GENOMICS RESEARCHER TO LECTURE
AT HOMICIDE INVESTIGATORS TRAINING SEMINAR**

SARASOTA, Fla., Sept. 21, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) announced today that Matt Thomas, Ph.D., Senior Scientist and Manager of Laboratory Operations for the Company, will be a scheduled guest lecturer at a seminar that will be part of the annual Mid-States Homicide Investigators Association Conference, to be held October 11 through 13, 2006, at the Hotel at Old Town in Wichita, Kan.

Dr. Thomas will deliver a presentation titled, "Overview of DNAWitness™ and Case Histories," which is designed to acquaint law enforcement officials with the capabilities of the DNAPrint Genomics's DNAWitness™ product and how it has helped to solve a variety of cases. Dr. Thomas is slated to appear on Thursday, October 12 at 11:00 a.m.

"We are pleased that Dr. Thomas was chosen to participate in this forensics course," said DNAPrint Chief Scientific Officer, Tony Frudakis, PhD. "This demonstrates the real value that our DNAWitness™ technology adds to investigations that are currently being conducted all over the world. We are especially pleased that DNAWitness™ is being used in this course as an example of the latest advances in DNA technology and its potential for solving so-called 'cold' cases."

The three-day course, titled "Homicide Investigation, Cold Case," is designed to address the challenges which face first responders - officers, detectives, supervisors, and crime scene investigators - when they recognize the prospect of investigating and prosecuting a difficult homicide case. Other presenters include law enforcement officials from the FBI and from several jurisdictions in the Mid West, as well as Bill Kurtis, producer and host of Cold Case Files on the A&E cable network.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry

(MORE)

heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness (TM), RETINOME(TM), AncestrybyDNA(TM) and EuroDNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###